SEREVENT

GlaxoSmithKline LLC🇺🇸 United States

FDA Page

Effective Date: Oct 10, 2022
Approval ID: 12d9728e-6b5c-4aee-bfb0-745e542ed2e4
Products: 1 registered
Version: 32

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use SEREVENT DISKUS safely and effectively. See full prescribing information for SEREVENT DISKUS. SEREVENT DISKUS (salmeterol xinafoate inhalation powder), for oral inhalation useInitial U.S. Approval: 1994

Quick Stats

Total Products1

Labelers2

Label Sections19

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.